

HIGHMARK | HIGHMARK

MEDICAL POLICY UPDATE

February 2026

IN THIS ISSUE

Commercial Policy Changes:	1
Medicare Advantage Policy Changes:	5
Evolent Policies:.....	6
Additional Notifications - Commercial:	10
Coding Update: Highmark has revised coding for Cosmetic Surgery vs. Reconstructive Surgery.....	10
Evolent to Manage Medical and Radiation Oncology Services	11
New Criteria: Highmark Management of Musculoskeletal Policies and Guidelines.....	11
Revised Criteria: Highmark has revised the criteria for Serum Biomarker Panel Testing for Systemic Lupus Erythematosus	14
New Policy: Highmark has Established New Criteria for Electrocardiography	14
Revised Criteria: Highmark has Revised the Criteria for Intra-Arterial/Intravenous Therapeutic Procedures.....	14

Policy

This notification provides an overview of upcoming medical policy changes affecting our Commercial and Medicare Advantage lines of business. Details are outlined in the tables below.

For new policies or those with updated criteria, a direct link is provided in the title of each policy. This link will allow you to view a draft version highlighting the specific changes. Within the draft, additions to the policy are indicated by red underlined text, while deletions are shown as highlighted text with a strikethrough.

Commercial Policy Changes:

Policy Category	Policy Number and Title	Anticipated Issue Date	Impacted States
New Policy	L-314 - Chemotherapy Sensitivity Assays	4/6/2026	All
New Policy	M-97 - Electrocardiography (EKG/ECG)	5/25/2026	All
New Policy	R-90 - Radiation Therapy for Non-Malignant Disease	5/1/2026	All

New Policy	X-591 - Appropriate Use of Imaging for Plantar Fasciitis	5/25/2026	All
Criteria Update	I-100 - Cetuximab (Erbix)	5/18/2026	New York
Criteria Update	I-109 - Irinotecan (Camptosar)	5/18/2026	New York
Criteria Update	I-113 - Ado-trastuzumab emtansine (Kadcyla)	5/18/2026	New York
Criteria Update	I-117 - Panitumumab (Vectibix)	5/18/2026	New York
Criteria Update	I-158 - Pegaspargase (Oncaspar), Asparaginase Erwinia Chrysanthemii (Erwinaze), and Calaspargase Pegol-mknl (Asparlas)	5/18/2026	New York
Criteria Update	I-159 - Oncologic Indications for Histone Deacetylase (HDAC) Inhibitors	5/18/2026	New York
Criteria Update	I-170 - Siltuximab (Sylvant)	5/18/2026	New York
Criteria Update	I-175 - Octreotide acetate (Sandostatin, Sandostatin LAR) and Lanreotide (Somatuline Depot)	5/1/2026	Pennsylvania, West Virginia, Delaware
Criteria Update	I-180 - Chimeric Antigen Receptor T-Cell Therapy	3/2/2026	All
Criteria Update	I-185 - Inotuzumab Ozogamicin (Besponsa)	4/13/2026	New York
Criteria Update	I-201 - Treatment of Transthyretin-Mediated Amyloidosis	2/23/2026	All
Criteria Update	I-227 - Inebilizumab-cdon (Uplizna)	3/2/2026	All
Criteria Update	I-241 - Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpui (Rybrevant Faspro)	3/2/2026	All
Criteria Update	I-265 - Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo)	3/2/2026	DE
Criteria Update	I-265 - Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo)	3/2/2026	New York, West Virginia
Criteria Update	I-265 - Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo)	3/2/2026	Pennsylvania
Criteria Update	I-30 - Denosumab (Prolia, Xgeva) and Denosumab Biosimilars	3/2/2026	All
Criteria Update	I-34 - Ipilimumab (Yervoy)	5/11/2026	New York
Criteria Update	I-4 - Hemophilia Treatment Clotting Factors/Coagulant Blood Products	3/2/2026	All
Criteria Update	I-87 - Oxaliplatin (Eloxatin)	5/18/2026	New York
Criteria Update	I-88 - Granulocyte Colony-Stimulating Factors	3/2/2026	All
Criteria Update	I-94 - Intravitreal Injections	3/2/2026	All
Criteria Update	I-98 - Bendamustine (Treanda, Bendeka, Belrapzo, Vivimusta)	5/18/2026	New York
Criteria Update	L-10 - Selected Tests for Rheumatic Diseases	5/25/2026	All
Criteria Update	L-264 - Serum Biomarker Panel Testing for Systemic Lupus Erythematosus	5/25/2026	All
Criteria Update	L-265 - Comprehensive Tumor Sequencing	4/6/2026	New York
Criteria Update	L-4 - Intraepidermal Nerve Fiber Density Testing	4/6/2026	All
Criteria Update	S-74 - Suction Assisted Lipectomy (SAL)	4/6/2026	All
Criteria Update	S-82 - Intra-Arterial/Intravenous Therapeutic Procedures	5/25/2026	All
Criteria Update	S-184 - Gender Affirmation Treatment	4/06/2026	New York
Criteria Update	Y-12 - Urinary Incontinence Therapy	4/6/2026	All

Criteria Update	<u>Z-109 - Outpatient Surgery Site of Care</u>	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-100 - Cetuximab (Erbix)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-109 - Irinotecan (Camptosar)	5/1/2026	Pennsylvania, West Virginia, Delaware
Archive	I-112 - Ziv-aflibercept (Zaltrap)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-113 - Ado-trastuzumab emtansine (Kadcyla)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-117 - Panitumumab (Vectibix)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-136 - Brentuximab Vedotin (Adcetris)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-147 - Talimogene Laherparepvec (Imlygic)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-148 - Ramucirumab (Cyramza)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-158 - Pegaspargase (Oncaspar), Asparaginase Erwinia Chrysanthemi (Erwinaze), and Calaspargase Pegol-mknl (Asparlas)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-159 - Oncologic Indications for Histone Deacetylase (HDAC) Inhibitors	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-170 - Siltuximab (Sylvant)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-181 - Pralatrexate (Folotyn)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-185 - Inotuzumab Ozogamicin (Besponsa)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-226 - Tafasitamab-cxix (Monjuvi)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-235 - Margetuximab-cmkb (Margenza)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-248 - Tebentafusp-tebn (Kimmtrak)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-275 - Talquetamab-tgvs (Talvey)	5/1/2026	Pennsylvania, Delaware, West Virginia

Archive	I-276 - Elranatamab-bcmm (Elrexio)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-277 - Intra-arterial Melphalan (Hepzato)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-287 - Nogapendekin alfa inbakicept-pmln (Anktiva)	5/1/2026	Pennsylvania, Delaware, West Virginia
Archive	I-34 - Ipilimumab (Yervoy)	5/1/2026	Pennsylvania, West Virginia, Delaware
Archive	I-87 - Oxaliplatin (Eloxatin)	5/1/2026	Pennsylvania, West Virginia, Delaware
Archive	I-98 - Bendamustine (Treanda, Bendeka, Belrapzo, Vivimusta)	5/1/2026	Pennsylvania, Delaware, West Virginia
No Change in Coverage	E-36 - Speech Generating Devices	4/6/2026	All
No Change in Coverage	I-112 - Ziv-aflibercept (Zaltrap)	4/6/2026	New York
No Change in Coverage	I-136 - Brentuximab Vedotin (Adcetris)	4/20/2026	New York
No Change in Coverage	I-147 - Talimogene Laherparepvec (Imlygic)	4/6/2026	New York
No Change in Coverage	I-148 - Ramucirumab (Cyramza)	4/6/2026	New York
No Change in Coverage	I-175 - Octreotide acetate (Sandostatin, Sandostatin LAR) and Lanreotide (Somatuline Depot)	4/6/2026	New York
No Change in Coverage	I-181 - Pralatrexate (Folotyn)	4/20/2026	New York
No Change in Coverage	I-226 - Tafasitamab-cxix (Monjuvi)	4/20/2026	New York
No Change in Coverage	I-235 - Margetuximab-cmkb (Margenza)	4/20/2026	New York
No Change in Coverage	I-248 - Tebentafusp-tebn (Kimmtrak)	4/13/2026	New York
No Change in Coverage	I-275 - Talquetamab-tgvs (Talvey)	5/1/2026	New York
No Change in Coverage	I-276 - Elranatamab-bcmm (Elrexio)	5/1/2026	New York
No Change in Coverage	I-277 - Intra-arterial Melphalan (Hepzato)		New York
No Change in Coverage	I-287 - Nogapendekin alfa inbakicept-pmln (Anktiva)	5/1/2026	New York
No Change in Coverage	L-311 - Laboratory Thyroid Testing in Adults	4/6/2026	All
No Change in Coverage	L-42 - Rapid Platelet Function Assay - ASA	4/6/2026	All
No Change in Coverage	M-90 - Single Photon Emission Computed Tomography (SPECT)	4/6/2026	All
No Change in Coverage	Q-5 - Ambulance Services: Air and Water	4/20/2026	All
No Change in Coverage	S-157 - Extracorporeal Shock Wave Therapy for Musculoskeletal Conditions and Soft Tissue Wounds	4/6/2026	All

No Change in Coverage	S-284 - Ankle Arthroscopy	4/6/2026	All
No Change in Coverage	S-334 - Repair, Metatarsal	4/13/2026	All
No Change in Coverage	S-336 - Hallux Rigidus Correction	4/13/2026	All
No Change in Coverage	S-552 - Sclerotherapy (Liquid or Microfoam)	4/6/2026	All
No Change in Coverage	V-16 - Speech Therapy	4/6/2026	All
No Change in Coverage	Z-11 - Definition of Medical Necessity	4/6/2026	All
No Change in Coverage	Z-111 - Category III Codes	4/6/2026	All
No Change in Coverage	Z-29 - Hypnosis	4/6/2026	All
No Change in Coverage	Z-50 - Determination of Refractive State	4/6/2026	All

Medicare Advantage Policy Changes:

Policy Category	Policy Number and Title	Anticipated Issue Date	Impacted States
Criteria Update	MA I-175 - Octreotide acetate (Sandostatin, Sandostatin LAR) and Lanreotide (Somatuline Depot)	5/1/2026	MA Pennsylvania, MA Delaware, MA New York
Criteria Update	MA I-275 - Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo)	3/2/2026	All
Criteria Update	MA N-24 NY - Miscellaneous Services	6/30/2025	MA New York
Criteria Update	MA N-24 PA/DE/WV - Miscellaneous Services	6/30/2025	MA Pennsylvania, MA Delaware, MA West Virginia
Criteria Update	MA Z-129 - Outpatient Surgery Site of Care	5/1/2026	MA West Virginia
Criteria Update	MA Z-129 - Outpatient Surgery Site of Care	5/1/2026	MA Pennsylvania, MA Delaware
Archive	MA I-112 - Ziv-aflibercept (Zaltrap)	5/1/2026	All
Archive	MA I-113 - Ado-trastuzumab emtansine (Kadcyla)	5/1/2026	All
Archive	MA I-117 - Panitumumab (Vectibix)	5/1/2026	All
Archive	MA I-136 - Brentuximab Vedotin (Adcetris)	5/1/2026	All
Archive	MA I-147 - Talimogene Laherparepvec (Imlygic)	5/1/2026	All
Archive	MA I-148 - Ramucirumab (Cyramza)	5/1/2026	All
Archive	MA I-158 - Pegaspargase (Oncaspar), Asparaginase Erwinia Chrysanthemii (Rylaze), and Calaspargase Pegol-mknl (Asparlas)	5/1/2026	All
Archive	MA I-159 - Oncologic indications for Histone deacetylase (HDAC) inhibitors	5/1/2026	All
Archive	MA I-170 - Siltuximab (Sylvant)	5/1/2026	All
Archive	MA I-181 - Pralatrexate (Folotylin)	5/1/2026	All

Archive	MA I-185 - Inotuzumab Ozogamicin (Besponsa)	5/1/2026	All
Archive	MA I-233 - Tafasitamab-cxix (Monjuvi)	5/1/2026	All
Archive	MA I-24 - Irinotecan (Camptosar)	5/1/2026	All
Archive	MA I-243 - Margetuximab-cmkb (Margenza)	5/1/2026	All
Archive	MA I-257 - Tebentafusp-tebn (Kimmtrak)	5/1/2026	All
Archive	MA I-284 - Talquetamab-tgvs (Talvey)	5/1/2026	All
Archive	MA I-285 - Elranatamab-bcmm (Elrexio)	5/1/2026	All
Archive	MA I-286 - Intra-arterial Melphalan (Heprato)	5/1/2026	All
Archive	MA I-297 - Nogapendekin alfa inbakicept-pmln (Anktiva)	5/1/2026	All
Archive	MA I-48 - Oxaliplatin (Eloxatin)	5/1/2026	All
Archive	MA I-55 - Bendamustine (Treanda, Bendeka, Belrapzo, Vivimusta)	5/1/2026	All
Archive	MA I-59 - Ipilimumab (Yervoy)	5/1/2026	All
Archive	MA I-69 - Cetuximab (Erbix)	5/1/2026	All

Evolut Policies:

Policy Category	Policy Number and Title	Anticipated Issue Date	Impacted States
New	ECG 3000- Abraxane (nab-paclitaxel)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3001 - Adakveo (crizanlizumab-tmca)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3002 - Adstiladrin (nadofaragene firadenovec-vncq)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3003 - Asparlas (calaspargase pegol-mknl)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3007 - Criteria Evidence-Based Cancer Therapies	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3008 - Datroway (datopotamab deruxtecandink)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3011 - Kadcyła (ado-trastuzumab emtansine)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3013 - Libtayo (cemiplimab-rwlc)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3015 - Lunsumio (mosunetuzumab-axgb)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3016 - Margenza (margetuximab-cmkb)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3017 - Oncaspar (pegaspargase)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3018 - Opdivo and Opdivo Qvantig (nivolumab IVSC)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3023 - Vectibix (panitumumab)	5/1/2026	Pennsylvania, Delaware, West Virginia

New	ECG 3026 - Yondelis (trabectedin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3027 - Zaltrap (ziv-aflibercept)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3028 - Zepzelca (lurbinectedin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3029 - Zynyz (retifanlimab-dlwr)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3031 - Adcetris (brentuximab vedotin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3033 - Clolar (clofarabine)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3034 - Cosela (trilaciclib)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3035 - Enhertu (fam-trastuzumab deruxtecan-nxki)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3038 - Gazyva (obinutuzumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3039 - Generic Drugs	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3043 - Orserdu (elacestrant)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3046 - Rituximab Products	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3049 - Tevimbra (tislelizumab-jsqr)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3058 - Fusilev, Khapzory (levoleucovorin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3061 - Besponsa (inotuzumab ozogamicin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3066 - Inqovi (decitabine and cedazuridine)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3073 - Trastuzumab Products, Pertuzumab Products, and Phesgo	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3074 - Bone Modifying Agents	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3075- Elahere (mirvetuximab soravtansine-qynx)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3076 - Erythropoiesis Stimulating Agents	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3080 - Doxil (liposomal doxorubicin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3087 - Bavencio (avelumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3090 - Elzonris (tagraxofusp)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3095 - Elitek (rasburicase)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3104 - Radiopharmaceuticals	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3105 - Imfinzi (durvalumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3106 - Myeloid Growth Factors (MGFs)	5/1/2026	Pennsylvania, Delaware, West Virginia

New	ECG 3107 - Ziihera (zanidatamab-hrii)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3108- Unloxcyt (cosibelimab-ipdl)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3112 - Voraxaze (glucarpidase)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3113 - Nplate (romiplostim)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3120 - Polivy (polatuzumab vedotin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3121 - Padcev (entumab vedotin-ejfv)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3122 - Monjuvi (tafasitamab-cxix)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3123 - Jelmyto (mitomycin pyelocalyceal instillation)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3124 - Zynlonta (loncastuximab tesirine-lpyl)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3125 - Mozobil (plerixa)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3128 - Anktiva (nogapendekin alfa inbakicept-pmn)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3130 - Penpulimab-kcqx (penpulimab-kcqx)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3132 - Emrelis (telisotuzumab vedotin-tllv)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3133 - Imjudo (tremelimumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3136 - Istodax (romidepsin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3137 - Ixempra (ixabepilone)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3140 - Cablivi (caplacizumab-yhdp)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3144 - Sylvant (siltuximab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3149- Tivdak (tisotumab vedotin-tftv)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3150 - Epkinly (epcoritamab-bysp)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3151 - Imdelltra (tarlatamab-dlle)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3153 - Zusduri (mitomycin intravesical solution)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3154 - Bevacizumab Products	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3155 - Yervoy (ipilimumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3157- Lynozyfic (linvoseltamab-qcpt)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3159 - Keytruda and Keytruda Qlex (pembrolizumab IVSC)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3160 - Darzalex and Darzalex Faspro (daratumumab IVSC)	5/1/2026	Pennsylvania, Delaware, West Virginia

New	ECG 3161 - Reblozyl (luspatercept-aamt)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3162 - Valstar (valrubicin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3164- Halaven (eribulin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3165 - Treanda Bendeka Belrapzo Vivimusta (bendamustine)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3166 - Mylotarg (gemtuzumab ozogamicin)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3170 - Columvi (glofitamab-gxhm)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3174 - Rytelo (imetelstat)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3178 - Jemperli (dostarlimab-gxly)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3179 - Opdualag (nivolumab and relatlimab-rmbw)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3180 - Elrexio (elranatamab-bcmm)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3181 - Talvey (talquetamab-tqvs)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3187 - Jevtana (cabazitaxel)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3189 - Inlexzo (gemcitabine intravesical system)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3190 - Alimta Pemfexy Axtle Pemrydi (pemetrexed)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3192 - Cyramza (ramucirumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3198 - Sarclisa (isatuximab-irfc)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3201 - Hepzato (melphalan)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3202 - Lymphir (denileukin diftitox-cxdl)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3204 - Erbitux (cetuximab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3211 - Kyprolis (carfilzomib)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3213- Empliciti (elotuzumab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3236 - Onivyde (irinotecan liposome)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3239 - Vyxeos (daunorubicin and cytarabine liposomal)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3241 - Clinical Drug Trial	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3243 - Tecvayli (teclistamab-cqyv)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3245 - Adzynma (ADAMTS13, recombinant-krhn)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 3247 - Loqtorzi (toripalimab-tpzi)	5/1/2026	Pennsylvania, Delaware, West Virginia

New	ECG 3251- Vyloy (zolbetuximab-clzb)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 7000 -Radiation Therapy Services	5/1/2026	Pennsylvania, Delaware, West Virginia
New	ECG 7001 -Proton Beam Radiation Therapy and Neutron Beam Radiation Therapy Services	5/1/2026	Pennsylvania, Delaware, West Virginia
New	EMOD.0001- Medical Oncology Drug List Policy	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1042 - Somatostatin Analog	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1260- Beleodaq (belinosat)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1270- Blinicyto (blinatumomab)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1282- Imlygic (Talimogene Laherparepvec)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1361- Rylaze (asparaginase Erwinia chrysanthemi recombinant-rywn)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1407 - Trodelvy (sacituzumab govitecan-hziy)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1441- Rybrevant (amivantamab-vmjw)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1459- Kimmtrak (tebentafusp-tebn)	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1468 - Antiemetics	5/1/2026	Pennsylvania, Delaware, West Virginia
New	UM ONC 1519- Bizengri (zenocutuzumab-zbco)	5/1/2026	Pennsylvania, Delaware, West Virginia



Policy

Additional Notifications - Commercial:

Coding Update: Highmark has revised coding for Cosmetic Surgery vs. Reconstructive Surgery



A procedure code was inadvertently placed on S-28, Cosmetic Surgery vs. Reconstructive Surgery. The policy has been updated to remove the code from the panniculectomy section as of February 13, 2026. No other changes were made to the policy.

Please refer to Medical Policy S-28, Cosmetic Surgery vs. Reconstructive Surgery, for additional information.

Evolent to Manage Medical and Radiation Oncology Services



Beginning May 1, 2026, Evolent, a specialty care enablement company, will manage medical and radiation oncology authorization requests for Highmark. Evolent will manage oncology care for the states of PA, WV and DE for the commercial line of business and for all states for the Medicare Advantage line of business.

Please refer to the list of [Evolent policies](#) Highmark will be adopting within this newsletter for details regarding clinical criteria.

New Criteria: Highmark Management of Musculoskeletal Policies and Guidelines



Highmark will be assuming management of musculoskeletal policies and guidelines effective May 1, 2026. The following list represents the policies and guidelines that will be instituted for Pennsylvania, Delaware, and West Virginia. Any fully adopted policies from MCG are viewable in CGT which can be accessed under the Licensed Criteria on the Medical Policy Search Page.

These medical policies will apply to professional providers and facility claims. The effective date is May 1, 2026.

Policy Number	Policy Title
A-0216	Knee Surgery: Meniscal Allograft Transplantation
A-0218	Facet Neurotomy
A-0226	Vertebroplasty and Kyphoplasty
A-0227	Disk Arthroplasty, Cervical
A-0229	Nerve Block or Neurolysis, Lumbar Sympathetic
A-0230	Nerve Block, Stellate Ganglion
A-0415	Autologous Chondrocyte Implantation, Knee
A-0416	Mosaicplasty
A-0506	Knee Surgery: Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions
A-0565	Bone Growth Stimulators, Electrical and Electromagnetic
A-0695	Facet Joint Injection
P-1056	Spine, Scoliosis, Posterior Instrumentation, Pediatric
S-1045	Shoulder Arthroscopy
S-1056	Spine, Scoliosis, Posterior Instrumentation
S-285	Spinal Cord and Dorsal Root Ganglion Stimulation
S-287	Recombinant Human Bone Morphogenetic Protein (rhBMP2) (InFuse)
S-293	Facet Joint and Peripheral Nerve Ablation/Denervation
S-294	Drug Delivery Systems, Implantable Intrathecal
S-295	Intradiscal Procedures
S-299	Knee Replacement, Partial

S-302	Spinal Decompression, Lumbar
S-303	Knee Surgery: Anteriolateral Ligament (ALL) Reconstruction
S-304	Knee Surgery: Abrasion Arthroplasty/Microfracturing/Subchondral Drilling
S-305	Knee Surgery: Patellofemoral
S-306	Knee Surgery: High Tibial Osteotomy
S-308	Shoulder Surgery: Loose Body/Foreign Body Removal
S-309	Shoulder Surgery: Debridement
S-311	Shoulder Surgery: Labral Repair
S-312	Shoulder Surgery: Biceps Tenodesis
S-313	Shoulder Surgery: Shoulder Instability and/or Laxity
S-315	Hip Surgery: Labral Repair or Reconstruction
S-316	Hip Surgery: Femoroacetabular Impingement (FAI)
S-317	Hip Surgery: Avascular Necrosis (AVN)
S-318	Hip Surgery: Synovectomy
S-319	Hip Surgery: Open or Arthroscopic
S-322	Decompression and Discectomy, Thoracic
S-323	Microdiscectomy, Lumbar
S-325	Lysis of Epidural Adhesions
S-326	Shoulder Surgery: Distal Clavicle Excision/Subacromial Decompression/Acromioplasty
S-560	Hip Arthroplasty
S-565	Hip Resurfacing
S-573	Disk Arthroplasty, Lumbar
S-582	Cervical Fusion, Anterior
S-583	Cervical Fusion, Posterior
S-585	Cervical Laminectomy
S-633	Shoulder Hemiarthroplasty
S-634	Shoulder Arthroplasty
S-700	Knee Arthroplasty, Total
S-705	Knee Arthroscopy
S-710	Knee Arthrotomy
S-770	Knee: Patella Reconstruction or Realignment
A-0216	Knee Surgery: Meniscal Allograft Transplantation
A-0218	Facet Neurotomy
A-0226	Vertebroplasty and Kyphoplasty
A-0227	Disk Arthroplasty, Cervical
A-0229	Nerve Block or Neurolysis, Lumbar Sympathetic
A-0230	Nerve Block, Stellate Ganglion
A-0415	Autologous Chondrocyte Implantation, Knee
A-0416	Mosaicplasty
A-0506	Knee Surgery: Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions
A-0565	Bone Growth Stimulators, Electrical and Electromagnetic
A-0695	Facet Joint Injection
P-1056	Spine, Scoliosis, Posterior Instrumentation, Pediatric

S-1045	Shoulder Arthroscopy
S-1056	Spine, Scoliosis, Posterior Instrumentation
S-285	Spinal Cord and Dorsal Root Ganglion Stimulation
S-287	Recombinant Human Bone Morphogenetic Protein (rhBMP2) (InFuse)
S-293	Facet Joint and Peripheral Nerve Ablation/Denervation
S-294	Drug Delivery Systems, Implantable Intrathecal
S-295	Intradiscal Procedures
S-299	Knee Replacement, Partial
S-302	Spinal Decompression, Lumbar
S-303	Knee Surgery: Anteriolateral Ligament (ALL) Reconstruction
S-304	Knee Surgery: Abrasion Arthroplasty/Microfracturing/Subchondral Drilling
S-305	Knee Surgery: Patellofemoral
S-306	Knee Surgery: High Tibial Osteotomy
S-308	Shoulder Surgery: Loose Body/Foreign Body Removal
S-309	Shoulder Surgery: Debridement
S-311	Shoulder Surgery: Labral Repair
S-312	Shoulder Surgery: Biceps Tenodesis
S-313	Shoulder Surgery: Shoulder Instability and/or Laxity
S-315	Hip Surgery: Labral Repair or Reconstruction
S-316	Hip Surgery: Femoroacetabular Impingement (FAI)
S-317	Hip Surgery: Avascular Necrosis (AVN)
S-318	Hip Surgery: Synovectomy
S-319	Hip Surgery: Open or Arthroscopic
S-322	Decompression and Discectomy, Thoracic
S-323	Microdiscectomy, Lumbar
S-325	Lysis of Epidural Adhesions
S-326	Shoulder Surgery: Distal Clavicle Excision/Subacromial Decompression/Acromioplasty
S-560	Hip Arthroplasty
S-565	Hip Resurfacing
S-573	Disk Arthroplasty, Lumbar
S-582	Cervical Fusion, Anterior
S-583	Cervical Fusion, Posterior
S-585	Cervical Laminectomy
S-633	Shoulder Hemiarthroplasty
S-634	Shoulder Arthroplasty
S-700	Knee Arthroplasty, Total
S-705	Knee Arthroscopy
S-710	Knee Arthrotomy
S-770	Knee: Patella Reconstruction or Realignment

Please refer to the listed medical policies as indicated for additional information.

Revised Criteria: Highmark has revised the criteria for Serum Biomarker Panel Testing for Systemic Lupus Erythematosus



Highmark has revised criteria for Serum Biomarker Panel Testing for Systemic Lupus Erythematosus. Serum biomarker panel testing for SLE and CTD is now considered not medically necessary.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is May 26, 2026.

Place of Service: Inpatient/Outpatient

Please refer to Medical Policy L-264, Serum Biomarker Panel Testing for Systemic Lupus Erythematosus, for additional information.

New Policy: Highmark has Established New Criteria for Electrocardiography



Highmark has established new criteria for electrocardiography. Electrocardiograms performed as a routine screening test during a preventive or annual wellness exam in the absence of signs, symptoms, or known disease will be considered not medically necessary.

This revised Medical Policy will apply to professional providers and/or facility claims. The effective date is May 25, 2026.

Place of Service: Inpatient/Outpatient

Please refer to Medical Policy M-97, Electrocardiography (EKG/ECG), for additional information.

Revised Criteria: Highmark has Revised the Criteria for Intra-Arterial/Intravenous Therapeutic Procedures



Highmark has revised criteria for intra-arterial/intravenous therapeutic procedures. Policy sections and indications are now more clearly defined. Criteria regarding diagnostic evidence and symptoms has been added to venous and arterial percutaneous transluminal angioplasty sections.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is May 25, 2026.

Place of Service: Inpatient/Outpatient

Please refer to Medical Policy S-82, Intra-Arterial/Intravenous Therapeutic Procedures, for additional information.



Comments on These Medical Policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of Medical Policy Update.

Write to us at MedicalPolicyInquiries@highmarkhealth.org



eSubscribe

Subscribe to receive electronic email updates and stay informed about changes to medical policies. Sign up here: [Provider Resource Center](#)



About this Newsletter

Medical Policy Update is a monthly newsletter for the health care providers who participate in our networks and submit claims to Highmark using the appropriate HIPAA transactions or claim forms as required by Highmark. This publication focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information, and updates, be sure to read *Provider News*, available on the [Provider Resource Center](#).

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life, Highmark Care Benefits Inc., or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to “Highmark” in this document are references to the Highmark company that is providing the member’s health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

Note: This publication may contain certain administrative requirements, policies, procedures, or other similar requirements of Highmark Inc. (or changes thereto) as well as interpretations of certain administrative requirements, policies and procedures (hereinafter collectively “requirements”) which are binding upon Highmark Inc. and its contracted providers. Therefore, the requirements in this publication supplement the Provider Manual. Pursuant to their contract, Highmark Inc. and such providers must comply with any requirements included herein unless and until such item(s) are subsequently modified in whole or in part.